Compare APT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | BTAI |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 49.2M |
| IPO Year | 1995 | 2018 |
| Metric | APT | BTAI |
|---|---|---|
| Price | $4.53 | $1.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 26.1K | ★ 578.0K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $59,096,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | $13.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.06 | $1.17 |
| 52 Week High | $6.20 | $9.26 |
| Indicator | APT | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 43.92 |
| Support Level | $4.49 | $1.82 |
| Resistance Level | $4.68 | $2.30 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 35.45 | 11.80 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.